CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hematologic cancers.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this CNE (NCPD) activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with hematologic cancers.
  
  LEARNING OBJECTIVES

  • Develop an understanding of the scientific rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences among commercially available and investigational products.
  • Consider the efficacy of approved and investigational CAR T-cell therapies directed at CD19 for relapsed/refractory B-cell lymphomas, and use this information to identify patients who may be candidates for this approach.
  • Evaluate recently presented data documenting the benefit of CAR T-cell therapy for relapsed/refractory chronic lymphocytic leukemia (CLL), and educate patients regarding the potential clinical role of this strategy.
  • Appreciate available data documenting the activity of CAR T-cell therapy directed against BCMA (the B-cell maturation antigen), and apply this knowledge to identify patients with multiple myeloma (MM) who may be appropriate for this approach as part of a clinical trial.
  • Recognize common adverse events associated with FDA-approved and investigational CAR T-cell therapies, and implement strategies to educate patients eligible for this treatment about the potential for these complications.
  • Recall ongoing research evaluating CAR T-cell-based approaches for various B-cell lymphomas, CLL and MM, and counsel appropriate patients regarding the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  CREDIT DESIGNATION STATEMENT
  NCPD credit is no longer available for this issue
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSCART2021/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: This NCPD activity consists of an audio component.
  NCPD credit is no longer available for this issue
  
  Video Program: This NCPD activity consists of a video component.
  NCPD credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Jeremy Abramson, MD
  Director, Center for Lymphoma
  Massachusetts General Hospital
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, bluebird bio, Bristol-Myers Squibb Company, C4 Therapeutics, Celgene Corporation, Genentech, a member of the Roche Group, Incyte Corporation, Juno Therapeutics, a Celgene Company, Kymera Therapeutics, MorphoSys; Contracted Research: Bristol-Myers Squibb Company, Seagen Inc.
  
  Caron Jacobson, MD
  Assistant Professor of Medicine
  Harvard Medical School
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, Kite, A Gilead Company, Lonza, Novartis, Precision BioSciences; Contracted Research: Kite, A Gilead Company, Pfizer Inc, Precision BioSciences.
  
  Noopur Raje, MD
  Director, Center for Multiple Myeloma
  Massachusetts General Hospital Cancer Center
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: Amgen Inc, bluebird bio, Celgene Corporation.
  
  Oncology Nurse Practitioners
  
  Sonia Glennie, ARNP, MSN, OCN
  Swedish Cancer Institute Center for Blood Disorders
  Seattle, Washington
  
  Speakers Bureau: Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company.
  
  Alli McClanahan, MSN, APRN, ANP-BC
  Nurse Practitioner
  Division of Hematology
  Mayo Clinic
  Rochester, Minnesota
  
  No relevant conflicts of interest to disclose.
  
  Elizabeth Zerante, MS, AGACNP-BC
  APN Inpatient Hematopoietic Cellular Therapy Service
  University of Chicago Medicine
  Chicago, Illinois
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
  
  RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Bristol-Myers Squibb Company.
  
  Release date: June 2021
  Expiration date: June 2022
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.